Results 191 to 200 of about 8,114 (214)

Nipocalimab: a significant milestone in the treatment of myasthenia gravis approved by the FDA. [PDF]

Ann Med Surg (Lond)
Irfan S, Sana M, Haque MA.
europepmc   +1 more source

Case Report: A Patient with Lambert-Eaton Myasthenic Syndrome Successfully Treated with Efgartigimod. [PDF]

Int Med Case Rep J
Han L, Shen J, Wei J, Zhang Y.
europepmc   +1 more source

Model-Informed Optimal Dosing of Anti-CD47 Antibody Using Target-Mediated Drug Disposition Model. [PDF]

Clin Transl Sci
Jeong S, Lee SY, Kim SH, Kim HT, Yun HY, Chae JW, Lee S.   +6 more
europepmc   +1 more source

Pharmacological considerations for next-generation protein therapeutics in cardiovascular disease. [PDF]

J Pharmacol Exp Ther
Lin E, Momin N.
europepmc   +1 more source

Potential drug interaction between calcitonin gene-related peptide antagonists and neonatal Fc receptor inhibitors. [PDF]

Headache
Harlan A, Weber K.
europepmc   +1 more source

Lactobacillus johnsonii-derived extracellular vesicles restore mucosal immunity via taurine-linked Th17/Treg and IgA/IgG regulation in colitis. [PDF]

J Nanobiotechnology
Zhao H, Yue N, Mai Z, Zhang Y, Tian C, Kong C, Huang L, Shi R, Liang Y, Yao J, Nie Y, Li D, Nie B, Wang L.   +13 more
europepmc   +1 more source

Engineering of the albumin-FcRn interaction

, 2017
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Albumin Binding to FcRn:  Distinct from the FcRn−IgG Interaction

Biochemistry, 2006
The MHC-related Fc receptor for IgG (FcRn) protects albumin and IgG from degradation by binding both proteins with high affinity at low pH in the acid endosome and diverting both from a lysosomal pathway, returning them to the extracellular compartment.
Chaity, Chaudhury, Charles L, Brooks, Daniel C, Carter, John M, Robinson, Clark L, Anderson   +4 more
openaire   +2 more sources